Cresco Labs Announces First Quarter 2021 Financial Results
CHICAGO–Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ), a vertically integrated multistate operator and a wholesaler of branded cannabis products, today announced its financial results for the first quarter ended March 31, 2021.
First Quarter 2021 Financial Highlights
- Revenue of $178.4 million, an increase of 9.9% quarter-over-quarter and 168.8% year-over-year
- Gross profit of $87.0 million, or 48.8% of revenue, an increase of 16.8% quarter-over-quarter and 268.9% year-over-year
- Adjusted EBITDA1 of $35.0million, an increase of 16.5% quarter-over-quarter and 507.2% year-over-year
- Record net wholesale revenue of $95.6 million, an increase of 5.7% quarter-over-quarter and 150.8% year-over-year
- Record retail revenue of $82.8 million from 24 stores, an increase of 15.2% quarter-over-quarter and 193.2% year-over-year
Financial Outlook
The Company is providing the following guidance:
- Annualized revenue run-rate of more than $1 billion by the end of 2021
- Gross profit margins in excess of 50% in the remaining three quarters of 2021
- Adjusted EBITDA1 margin run-rate of at least 30% by the end of 2021
Management Commentary
“In Q1, we delivered sequential growth from existing assets, demonstrated our ability to reach and sustain #1 market share positions in two of this industry’s top-five states, and we’re gearing up to repeat that success in more markets this year. We’re accelerating growth through a diverse set of initiatives including several organic expansions and M&A that will benefit the Company in subsequent quarters. In order to execute all of our pending growth initiatives, we invested in the operating platform to support the growth. We laid the groundwork in Q4 and Q1 and now our expertise with integrating new assets and producing operating leverage will kick in,” said Charles Bachtell, Co-Founder and CEO of Cresco Labs. “We’re also pleased to take this opportunity at the outset of the year to make the transition to U.S. GAAP, remove the break-out of certain one-time items, and provide investors with clarity on the transition. This represents another step to prepare Cresco Labs for the future opportunities that await in the U.S. capital markets. On a U.S. GAAP basis, we’re pleased with the growth in Q1 and excited about the steps we’ve taken so far this year to put Cresco Labs on the path to accelerate revenue, profitability, and shareholder value in 2021 and beyond.”
Balance Sheet and Liquidity
- As of March 31, 2021, current assets were $381.7 million, including cash and cash equivalents of $255.5 million. The Company had working capital of $105.1 million and term loan debt, net of issuance costs, of $187.9 million.
- Total shares outstanding on a fully converted basis were 399,018,710 as of March 31, 2021.
Capital Markets and M&A Activity
- On January 14, 2021, the Company entered into a definitive agreement with Bluma Wellness Inc. (CSE: BWEL.U) (OTCQX: BMWLF), a vertically integrated operator in Florida. After quarter-end, on April 14, 2021, the Company closed the acquisition of Bluma Wellness Inc.
- On January 14, 2021, the Company announced the commencement of a best efforts overnight marketed offering (the “Offering”) of Subordinate Voting Shares of the Company. On January 15, 2021, the Company closed the Offering for total gross proceeds of approximately $125.0 million.
- On February 16, 2021, the Company closed its acquisition of four Ohio dispensaries previously operated by Verdant Creations, LLC and its affiliates.
- On March 18, 2021, the Company entered into a definitive agreement to acquire all of the issued and outstanding equity interests in Cultivate Licensing LLC and BL Real Estate LLC, a vertically integrated Massachusetts operator.
Consolidated Financial Statements
The financial information reported in this press release is based on unaudited management prepared financial statements for the three months ended March 31, 2021. These financial statements have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). The Company expects to file its unaudited interim condensed consolidated financial statements on SEDAR on May 28, 2021. Accordingly, such financial information may be subject to change. All financial information contained in this press release is qualified in its entirety with reference to such financial statements. While the Company does not expect there to be any material changes between the information contained in this press release and the consolidated financial statements it files on SEDAR, to the extent that the financial information contained in this press release is inconsistent with the information contained in the Company’s financial statements, the financial information contained in this press release shall be deemed to be modified or superseded by the Company’s filed financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws. Further, the reader should refer to the additional disclosures in the Company’s audited financial statements for the year ended December 31, 2020, prepared under International Financial Reporting Standards (“IFRS”) and previously filed on SEDAR.
Cresco Labs references certain non-GAAP financial measures throughout this press release, which may not be comparable to similar measures presented by other issuers. Please see the “Non-GAAP Financial Measures” section of this press release for more detailed information.
U.S. GAAP Financial Reporting
Beginning with the quarter ended March 31, 2021, the Company has prepared its financial statements, including all comparative figures, in compliance with U.S. GAAP instead of IFRS. Changes to comparative figures for prior periods reflect their presentation in accordance with U.S. GAAP and is not a change in the Company’s underlying performance as previously reported under IFRS.
Non-GAAP Financial Measures
EBITDA and Adjusted EBITDA are non-GAAP measures and do not have standardized definitions under U.S. GAAP. The Company has provided these non-GAAP financial measures, which are not calculated or presented in accordance with U.S. GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with U.S. GAAP and may not be comparable to similar measures presented by other issuers. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believes that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the U.S. GAAP financial measures presented herein. Accordingly, the Company has included below reconciliations of the supplemental non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP. The Company has not quantitatively reconciled its guidance for forward-looking non-GAAP metrics to their most comparable U.S. GAAP measures because the Company does not provide specific guidance for the various reconciling items as certain items that impact these measures have not occurred, are out of the Company’s control, or cannot be reasonably predicted. Accordingly, a reconciliation to the most comparable U.S. GAAP financial metric is not available without unreasonable effort. Please note that the unavailable reconciling items could significantly impact the Company’s results.
Forward Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
1 See “Non-GAAP Financial Measures” at the end of this press release for more information regarding the Company’s use of non-GAAP financial measures.
Cresco Labs Inc. | ||||||||||||
Financial Information and Non-GAAP Reconciliations | ||||||||||||
(All amounts expressed in thousands of U.S. Dollars) | ||||||||||||
Unaudited Consolidated Statements of Operations | ||||||||||||
For the Three Months Ended March 31, 2021, December 31, 2020 and March 31, 2020 | ||||||||||||
For the Three Months Ended | ||||||||||||
($ in thousands) | March 31, 2021 | December 31, 2020 | March 31, 2020 | |||||||||
Revenue | $ | 178,437 | $ | 162,317 | $ | 66,380 | ||||||
Cost of goods sold | 91,414 | 87,835 | 42,792 | |||||||||
Gross profit | 87,023 | 74,482 | 23,588 | |||||||||
GP% | 48.8 | % | 45.9 | % | 35.5 | % | ||||||
Operating expenses: | ||||||||||||
Selling, general and administrative | 70,785 | 74,153 | 51,376 | |||||||||
Total operating expenses | 70,785 | 74,153 | 51,376 | |||||||||
Income (loss) from operations | 16,238 | 329 | (27,788) | |||||||||
Other (expense) income: | ||||||||||||
Interest expense, net | (11,302) | (7,939) | (6,796) | |||||||||
Other (expense) income, net | (12,340) | (18,469) | 10,455 | |||||||||
Loss from equity method investments | (1,196) | (927) | (144) | |||||||||
Total other (expense) income, net | (24,838) | (27,335) | 3,515 | |||||||||
Loss before income taxes | (8,600) | (27,006) | (24,273) | |||||||||
Income tax expense | (15,524) | (14,181) | (11,188) | |||||||||
Net income (loss) 1 | $ | (24,124) | $ | (41,187) | $ | (35,461) | ||||||
1 Net income (loss) includes amounts attributable to non-controlling interests. | ||||||||||||
Cresco Labs Inc. | ||||||||
Summarized Unaudited Consolidated Statements of Financial Position | ||||||||
As of March 31, 2021 and December 31, 2020 | ||||||||
($ in thousands) | March 31, | December 31, | ||||||
Cash and cash equivalents | $ | 255,503 | $ | 136,339 | ||||
Other current assets | 126,189 | 113,127 | ||||||
Property and equipment, net | 250,032 | 228,804 | ||||||
Intangible assets, net | 215,249 | 195,541 | ||||||
Goodwill | 459,701 | 450,569 | ||||||
Other non-current assets | 100,458 | 108,215 | ||||||
Total assets | $ | 1,407,132 | $ | 1,232,595 | ||||
Total current liabilities | 276,612 | 252,845 | ||||||
Total long-term liabilities | 420,139 | 404,418 | ||||||
Total shareholders’ equity | 710,381 | 575,332 | ||||||
Total liabilities and shareholders’ equity | $ | 1,407,132 | $ | 1,232,595 | ||||
Cresco Labs Inc. | ||||||||||||
Unaudited Reconciliation of Net Income to Adjusted EBITDA (Non-GAAP) | ||||||||||||
For the Three Months Ended March 31, 2021, December 31, 2020 and March 31, 2020 | ||||||||||||
For the Three Months Ended | ||||||||||||
($ in thousands) | March 31, | December 31, | March 31, | |||||||||
Net loss1 | $ | (24,124) | $ | (41,187) | $ | (35,461) | ||||||
Depreciation and amortization | 10,151 | 8,616 | 6,121 | |||||||||
Interest expense, net | 11,302 | 7,939 | 6,796 | |||||||||
Income tax expense | 15,524 | 14,181 | 11,188 | |||||||||
Earnings before interest, taxes, depreciation and amortization (EBITDA) (Non-GAAP) | $ | 12,853 | $ | (10,451) | $ | (11,356) | ||||||
Other expense (income), net | 12,340 | 18,469 | (10,455) | |||||||||
Loss from equity method investments | 1,196 | 927 | 144 | |||||||||
Fair value markup for acquired inventory | 585 | — | 1,575 | |||||||||
Adjustments for acquisition and other non-core costs | 1,738 | 15,540 | 9,369 | |||||||||
Management incentive compensation (share-based) | 6,280 | 5,545 | 2,129 | |||||||||
Adjusted EBITDA (Non-GAAP) | $ | 34,992 | $ | 30,030 | $ | (8,594) | ||||||
1 Net loss includes amounts attributable to non-controlling interests. | ||||||||||||
Cresco Labs Inc. | ||||||||||||
Unaudited Summarized Consolidated Statements of Cash Flows | ||||||||||||
For the Three Months Ended March 31, 2021, December 31, 2020 and March 31, 2020 | ||||||||||||
For the Three Months Ended | ||||||||||||
($ in thousands) | March 31, | December 31, | March 31, | |||||||||
Net provided by (used in) operating activities | $ | 12,950 | $ | 19,120 | $ | (38,159) | ||||||
Net cash used in investing activities | (26,790) | (8,795) | (52,151) | |||||||||
Net cash provided by financing activities | 132,206 | 71,021 | 107,456 | |||||||||
Effect of foreign currency exchange rate changes on cash | (169) | (190) | (122) | |||||||||
Net increase in cash and cash equivalents | $ | 118,197 | $ | 81,156 | $ | 17,024 | ||||||
Cash and cash equivalents and restricted cash, beginning of period | 140,774 | 59,618 | 53,009 | |||||||||
Cash and cash equivalents and restricted cash, end of period | $ | 258,971 | $ | 140,774 | $ | 70,033 | ||||||
Cresco Labs Inc. | ||||||||||||||||
Unaudited Consolidated Statements of Operations | ||||||||||||||||
For the Three Months Ended December 31, 2020, September 30, 2020, June 30, 2020, and March 31, 2020 | ||||||||||||||||
For the Three Months Ended | ||||||||||||||||
($ in thousands) | December 31, | September 30, | June 30, | March 31, | ||||||||||||
Revenue | $ | 162,317 | $ | 153,298 | $ | 94,256 | $ | 66,380 | ||||||||
Cost of goods sold | 87,835 | 76,454 | 62,469 | 42,792 | ||||||||||||
Gross profit | 74,482 | 76,844 | 31,787 | 23,588 | ||||||||||||
GP% | 45.9 | % | 50.1 | % | 33.7 | % | 35.5 | % | ||||||||
Expenses: | ||||||||||||||||
Selling, general and administrative | 74,153 | 51,909 | 52,725 | 51,376 | ||||||||||||
Total expenses | 74,153 | 51,909 | 52,725 | 51,376 | ||||||||||||
Income (loss) from operations | 329 | 24,935 | (20,938) | (27,788) | ||||||||||||
Other (expense) income: | ||||||||||||||||
Interest expense, net | (7,939) | (8,762) | (7,732) | (6,796) | ||||||||||||
Other (expense) income, net | (18,469) | (354) | 73 | 10,455 | ||||||||||||
(Loss) gain from equity method investments | (927) | (134) | 24 | (144) | ||||||||||||
Total other (expense) income, net | (27,335) | (9,250) | (7,635) | 3,515 | ||||||||||||
Income (loss) before income taxes | (27,006) | 15,685 | (28,573) | (24,273) | ||||||||||||
Income tax expense | (14,181) | 9,891 | (13,126) | (11,188) | ||||||||||||
Net income (loss) 1 | $ | (41,187) | $ | 25,576 | $ | (41,699) | $ | (35,461) | ||||||||
Depreciation and amortization | 8,616 | 8,641 | 8,410 | 6,121 | ||||||||||||
Interest expense, net | 7,939 | 8,762 | 7,732 | 6,796 | ||||||||||||
Income tax expense | 14,181 | (9,891) | 13,126 | 11,188 | ||||||||||||
Earnings before interest, taxes, depreciation and amortization (EBITDA) (Non-GAAP) | $ | (10,451) | $ | 33,088 | $ | (12,431) | $ | (11,356) | ||||||||
Other expense (income), net | 18,469 | 354 | (73) | (10,455) | ||||||||||||
Loss (gain) from equity method investments | 927 | 134 | (24) | 144 | ||||||||||||
Fair Value markup for acquired inventory | — | 1,843 | 331 | 1,575 | ||||||||||||
Adjustments for acquisition and other non-core costs | 15,540 | 1,413 | 3,526 | 9,369 | ||||||||||||
Management incentive compensation (share-based) | 5,545 | 3,335 | 7,831 | 2,129 | ||||||||||||
Adjusted EBITDA (Non-GAAP) | $ | 30,030 | $ | 40,166 | $ | (839) | $ | (8,594) | ||||||||
1 Net income (loss) includes amounts attributable to non-controlling interests. | ||||||||||||||||
(This information is primarily sourced from Cresco. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
About the Author: HCN News Team
Related Posts
